Can prophylactic HPV vaccination reduce the recurrence of cervical lesions after surgery? Review and prospect
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Can prophylactic HPV vaccination reduce the recurrence of cervical lesions after surgery? Review and prospect
Authors
Keywords
-
Journal
Infectious Agents and Cancer
Volume 18, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-29
DOI
10.1186/s13027-023-00547-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN 2-3: The VENUS Study
- (2022) Andrea Casajuana-Pérez et al. Vaccines
- HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions
- (2022) Carla Henere et al. Vaccines
- Myths and fake messages about human papillomavirus (HPV) vaccination: answers from the ESGO Prevention Committee
- (2022) Nadja Taumberger et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019
- (2021) Laia Bruni et al. PREVENTIVE MEDICINE
- Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation
- (2021) Arnaud John Kombe Kombe et al. Frontiers in Public Health
- Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis
- (2021) Violante Di Donato et al. Vaccines
- Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years
- (2021) Shujuan Lin et al. CANCER
- Human Papilloma Virus Vaccination
- (2021) Kendal Rosalik et al. Viruses-Basel
- If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment?
- (2021) Wiebren A.A. Tjalma et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial
- (2021) Carolina Porras et al. VACCINE
- Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial
- (2020) Mojgan Karimi-Zarchi et al. BMC PUBLIC HEALTH
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: the CVT Trial
- (2020) Sabrina H Tsang et al. JNCI-Journal of the National Cancer Institute
- Evaluation of durability of a single-dose of the bivalent HPV vaccine: the CVT Trial
- (2020) Aimée R Kreimer et al. JNCI-Journal of the National Cancer Institute
- The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease
- (2020) Anna Rosa Garbuglia et al. Frontiers in Immunology
- Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines
- (2020) Filipe Colaço Mariz et al. npj Vaccines
- HPV vaccination and cancer prevention
- (2020) A. Athanasiou et al. BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY
- Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: a meta-analysis
- (2020) Helena C Bartels et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women
- (2020) Katie Lichter et al. OBSTETRICS AND GYNECOLOGY
- HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions
- (2020) Marta del Pino et al. Vaccines
- The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation
- (2020) Jieliang Wang et al. AAPS PHARMSCITECH
- Prophylactic HPV vaccination after conization: A systematic review and meta-analysis
- (2020) M. Jentschke et al. VACCINE
- Parental intent to initiate and complete the human papillomavirus vaccine series in the USA: a nationwide, cross-sectional survey
- (2020) Kalyani Sonawane et al. Lancet Public Health
- Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study
- (2020) Joseph E Tota et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial
- (2020) Carolina Porras et al. LANCET ONCOLOGY
- Assessing the Long-Term Role of Vaccination against HPV after Loop Electrosurgical Excision Procedure (LEEP): A Propensity-Score Matched Comparison
- (2020) Giorgio Bogani et al. Vaccines
- Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) Wui-Jin Koh et al. Journal of the National Comprehensive Cancer Network
- HPV Vaccine: Updates and Highlights
- (2019) Cristina Mendes de Oliveira et al. ACTA CYTOLOGICA
- Recurrent disease after treatment for cervical pre-cancer: determining whether prophylactic HPV vaccination could play a role in prevention of secondary lesions
- (2019) L. S. Velentzis et al. CLIMACTERIC
- Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population
- (2019) Anna R. Giuliano et al. GYNECOLOGIC ONCOLOGY
- A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years
- (2019) Tino F. Schwarz et al. Human Vaccines & Immunotherapeutics
- Human papillomavirus and cervical cancer
- (2019) Kehinde Sharafadeen Okunade JOURNAL OF OBSTETRICS AND GYNAECOLOGY
- Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status
- (2019) Freja L. Sand et al. INTERNATIONAL JOURNAL OF CANCER
- Safety of the 9-Valent Human Papillomavirus Vaccine
- (2019) Tom T. Shimabukuro et al. PEDIATRICS
- Human papillomavirus vaccine against cervical cancer: Opportunity and challenge
- (2019) Renjie Wang et al. CANCER LETTERS
- Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis
- (2019) Marc Arbyn et al. Lancet Global Health
- ESGO Survey on Current Practice in the Management of Cervical Cancer
- (2018) Lukas Dostalek et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9–14 years: Results to month 36 from a randomized trial
- (2018) Ting Fan Leung et al. VACCINE
- Explanations for the high potency of HPV prophylactic vaccines
- (2018) John Schiller et al. VACCINE
- Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies
- (2018) Aimée R. Kreimer et al. VACCINE
- SPERANZA project: HPV vaccination after treatment for CIN2+
- (2018) Alessandro Ghelardi et al. GYNECOLOGIC ONCOLOGY
- Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials
- (2018) M. Arbyn et al. Expert Review of Vaccines
- Long-Lasting Increased Risk of Human Papillomavirus–Related Carcinomas and Premalignancies After Cervical Intraepithelial Neoplasia Grade 3: A Population-Based Cohort Study
- (2017) Renée M.F. Ebisch et al. JOURNAL OF CLINICAL ONCOLOGY
- Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
- (2017) Warner K Huh et al. LANCET
- Direct HPV E6/Myc interactions induce histone modifications, Pol II phosphorylation, and hTERT promoter activation
- (2017) Yiyu Zhang et al. Oncotarget
- Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection
- (2017) Maria Zurek Munk-Madsen et al. Human Vaccines & Immunotherapeutics
- Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age
- (2017) Tino F. Schwarz et al. Cancer Medicine
- Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials
- (2017) Ana Paula Ferreira Costa et al. Journal of Immunology Research
- Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment
- (2016) Allan Hildesheim et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014
- (2016) Joël Ladner et al. BMC HEALTH SERVICES RESEARCH
- Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy:Post-hocanalysis from a randomized controlled trial
- (2016) Suzanne M. Garland et al. INTERNATIONAL JOURNAL OF CANCER
- Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study
- (2016) Rengaswamy Sankaranarayanan et al. LANCET ONCOLOGY
- Antitumor dendritic cell–based vaccines: lessons from 20 years of clinical trials and future perspectives
- (2016) João Constantino et al. Translational Research
- Less than 3 doses of the HPV vaccine – Review of efficacy against virological and disease end points
- (2016) Partha Basu et al. Human Vaccines & Immunotherapeutics
- Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
- (2016) Julianne Gee et al. Human Vaccines & Immunotherapeutics
- Use of a 2-Dose Schedule for Human Papillomavirus Vaccination — Updated Recommendations of the Advisory Committee on Immunization Practices
- (2016) Elissa Meites et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects
- (2016) Erin M. Scherer et al. EBioMedicine
- From the monovalent to the nine-valent HPV vaccine
- (2015) S. Pils et al. CLINICAL MICROBIOLOGY AND INFECTION
- Development of a highly thermostable, adjuvanted human papillomavirus vaccine
- (2015) Kimberly J. Hassett et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Effect of vaccine administration modality on immunogenicity and efficacy
- (2015) Lu Zhang et al. Expert Review of Vaccines
- Cancer of the cervix: Early detection and cost-effective solutions
- (2015) Lynette Denny et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis
- (2015) Robine Donken et al. JOURNAL OF INFECTION
- Influence of a loop electrosurgical excision procedure (LEEP) on levels of cytokines in cervical secretions
- (2015) Audrey F. Saftlas et al. JOURNAL OF REPRODUCTIVE IMMUNOLOGY
- A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
- (2015) Elmar A. Joura et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9–15-Year-Old Girls
- (2015) Timo Vesikari et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine
- (2015) Suzanne M. Garland et al. VACCINE
- Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art
- (2015) Zheng Quan Toh et al. VACCINE
- Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease
- (2015) David Radley et al. Human Vaccines & Immunotherapeutics
- HPV vaccines: Translating immunogenicity into efficacy
- (2015) Taylor B. Turner et al. Human Vaccines & Immunotherapeutics
- Role of Cytokines in Genesis, Progression and Prognosis of Cervical Cancer
- (2014) Prajakta Hemant Paradkar et al. Asian Pacific Journal of Cancer Prevention
- Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review
- (2014) Ana Katherine Gonçalves et al. Brazilian Journal of Infectious Diseases
- Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types
- (2014) K Kavanagh et al. BRITISH JOURNAL OF CANCER
- Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs
- (2014) Sandra D Isidean et al. Expert Review of Vaccines
- Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality
- (2014) B. Strander et al. BMJ-British Medical Journal
- Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia
- (2014) E. Crowe et al. BMJ-British Medical Journal
- Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study
- (2013) Dorota M Gertig et al. BMC Medicine
- Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial
- (2013) M. Safaeian et al. Cancer Prevention Research
- HPV vaccine cross-protection: Highlights on additional clinical benefit
- (2013) Rosa De Vincenzo et al. GYNECOLOGIC ONCOLOGY
- Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2–3)?
- (2013) Woo Dae Kang et al. GYNECOLOGIC ONCOLOGY
- Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study
- (2013) Mark E. Scott et al. INTERNATIONAL JOURNAL OF CANCER
- Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women
- (2013) Simon R. M. Dobson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Human papillomavirus and cervical cancer
- (2013) Emma J Crosbie et al. LANCET
- HPV vaccine acceptability among men: a systematic review and meta-analysis
- (2013) Peter A Newman et al. SEXUALLY TRANSMITTED INFECTIONS
- The E1 proteins
- (2013) Monika Bergvall et al. VIROLOGY
- Prevention of Recurrent High-Grade Anal Neoplasia With Quadrivalent Human Papillomavirus Vaccination of Men Who Have Sex With Men: A Nonconcurrent Cohort Study
- (2012) K. A. Swedish et al. CLINICAL INFECTIOUS DISEASES
- Predictors of absence of cervical intraepithelial neoplasia in the conization specimen
- (2012) Agata Rodriguez-Manfredi et al. GYNECOLOGIC ONCOLOGY
- Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
- (2012) Talía Malagón et al. LANCET INFECTIOUS DISEASES
- Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study
- (2012) M. Rebolj et al. BMJ-British Medical Journal
- Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18
- (2011) A. Szarewski et al. INTERNATIONAL JOURNAL OF CANCER
- Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study
- (2011) Mariëlle Kocken et al. LANCET ONCOLOGY
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- (2011) Cosette M Wheeler et al. LANCET ONCOLOGY
- Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
- (2011) Anna R. Giuliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human Papillomavirus Vaccination Series Initiation and Completion, 2008-2009
- (2011) C. G. Dorell et al. PEDIATRICS
- Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica
- (2011) R. Herrero et al. Cancer Discovery
- HPV vaccine: Cervarix
- (2010) Anne Szarewski EXPERT OPINION ON BIOLOGICAL THERAPY
- Potential mechanisms for HPV vaccine-induced long-term protection
- (2010) Margaret Stanley GYNECOLOGIC ONCOLOGY
- Currently approved prophylactic HPV vaccines
- (2009) Diane M Harper Expert Review of Vaccines
- The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years
- (2009) Cosette M. Wheeler et al. JOURNAL OF INFECTIOUS DISEASES
- Interferon-γ (IFN-γ): A possible prognostic marker for clearance of high-risk human papillomavirus (HPV)
- (2008) Seung-Hun Song et al. GYNECOLOGIC ONCOLOGY
- Intradermal vaccine delivery: Will new delivery systems transform vaccine administration?
- (2008) Paul Henri Lambert et al. VACCINE
- Interaction of human papillomaviruses with the host immune system: A well evolved relationship
- (2008) Ian H. Frazer VIROLOGY
- Papillomavirus E6 proteins
- (2008) Heather L. Howie et al. VIROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started